← Back to Search

Device

Oxygen Titration Strategies for Respiratory Insufficiency (Oxygap pong Trial)

Quebec, Canada
N/A
Recruiting
Research Sponsored by Laval University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up mean oxygen flow in the two last minute of each study period (between minute 8 and 10)
Awards & highlights
No Placebo-Only Group

Summary

This trial found that different oximeters provide different readings, and oxygen flow should take into account oximeter choice and SpO2 target.

See full description
Who is the study for?
Adults in postoperative cardiac surgery ICU on moderate oxygen therapy (up to 5L/min) with specific SpO2 levels, who have an arterial catheter and don't expect to change respiratory support within an hour. Excluded are those with certain blood conditions, no oximeter signal, nail coverings, or isolation due to infection.
What is being tested?
The trial is testing how different oxygenation targets (90% vs. 94% SpO2) affect oxygen flow rates when using two types of oximeters (Philips and Nonin). It aims to determine if the target and device choice impact the amount of oxygen needed by patients.See study design
What are the potential side effects?
While not explicitly stated for this trial, potential side effects may include issues related to prolonged oxygen therapy such as dry or bloody nose, fatigue, morning headaches and in severe cases lung damage from high concentrations of oxygen.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~mean oxygen flow in the two last minute of each study period (between minute 8 and 10)
This trial's timeline: 3 weeks for screening, Varies for treatment, and mean oxygen flow in the two last minute of each study period (between minute 8 and 10) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Oxygen flow (or FiO2)
Secondary study objectives
Difference between SpO2 and SaO2
Other study objectives
Complete oxygen weaning
Mean difference on oxymeter
Occult hyperoxemia
+3 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Experimental Treatment
Group I: Philips oximeter with a 94% SpO2 targetExperimental Treatment1 Intervention
During this periods, oxygen will be administered in a manual titration with the FreeO2 device (fixed flow mode), to reach 94% of SpO2.
Group II: Philips oximeter with a 90% SpO2 targetExperimental Treatment1 Intervention
During this periods, oxygen will be administered in a manual titration with the FreeO2 device (fixed flow mode), to reach 90% of SpO2.
Group III: Nonin oximeter with a 94% SpO2 targetExperimental Treatment1 Intervention
During this periods , oxygen will be administered in a manual titration with the FreeO2 device (fixed flow mode) to reach 94% of SpO2.
Group IV: Nonin oximeter with a 90% SpO2 targetExperimental Treatment1 Intervention
During this periods , oxygen will be administered in an manual titration with the FreeO2 device (fixed flow mode) to reach 90% of SpO2.

Find a Location

Closest Location:Institut Universitaire de Cardiologie et de Pneumologie de Québec· Quebec, Canada

Who is running the clinical trial?

Laval UniversityLead Sponsor
438 Previous Clinical Trials
177,682 Total Patients Enrolled
3 Trials studying Oxygen Toxicity
338 Patients Enrolled for Oxygen Toxicity

Media Library

Nonin oximeter (SpO2 target 90%) (Device) Clinical Trial Eligibility Overview. Trial Name: NCT05590130 — N/A
Oxygen Toxicity Research Study Groups: Nonin oximeter with a 94% SpO2 target, Philips oximeter with a 94% SpO2 target, Philips oximeter with a 90% SpO2 target, Nonin oximeter with a 90% SpO2 target
Oxygen Toxicity Clinical Trial 2023: Nonin oximeter (SpO2 target 90%) Highlights & Side Effects. Trial Name: NCT05590130 — N/A
Nonin oximeter (SpO2 target 90%) (Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05590130 — N/A
~12 spots leftby Mar 2026